Advanced search
Publication Cover
Expert Review of Vaccines Volume 15, 2016 - Issue 2
Submit an article Journal homepage
616
Views
22
CrossRef citations to date
0
Altmetric
Reviews

Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses

Charles J. RussellDepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, USA;Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA
&
Julia L. HurwitzDepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, USA;Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USACorrespondence[email protected]
Pages 189-200 | Received 27 Aug 2015, Accepted 27 Oct 2015, Published online: 09 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555.
  • Shi T, McLean K, Campbell H, et al. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Glob Health. 2015;5(1):010408.

• This paper describes serious pediatric diseases caused by respiratory viruses worldwide.

  • Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102(3A):2–9; discussion 25–26.
  • Lamb RA, Parks GD. Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE et al., editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 1449–1496.
  • Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25(9):795–800.
  • Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013;368(7):633–643.
  • Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–546.
  • Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–598.
  • Henrickson KJ. Lower respiratory viral infections in immunocompetent children. Adv Pediatr Infect Dis. 1994;9:59–96.
  • Shaw CA, Ciarlet M, Cooper BW, et al. The path to an RSV vaccine. Curr Opin Virol. 2013;3(3):332–342.
  • Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum Vaccin. 2009;5(9):582–591.
  • Marks MI. Respiratory syncytial virus infections. Clin Pediatr. 1992;31(11):688–691.
  • Hacimustafaoglu M, Celebi S, Aynaci E, et al. The progression of maternal RSV antibodies in the offspring. Arch Dis Child. 2004;89(1):52–53.
  • Shinoff JJ, O’Brien KL, Thumar B, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis. 2008;198(7):1007–1015.
  • Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34–42.
  • Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652–665.
  • Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–e51.
  • Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest. 2002;110(1):21–27.
  • Ahmed JA, Katz MA, Auko E, et al. Epidemiology of respiratory viral infections in two long-term refugee camps in Kenya, 2007–2010. BMC Infect Dis. 2012;12(7):1–8.
  • Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr. 2009;154(5):694–699.
  • Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis. 1994;18(5):770–779.
  • Groome MJ, Moyes J, Cohen C, et al. Human metapneumovirus-associated severe acute respiratory illness hospitalisation in HIV-infected and HIV-uninfected South African children and adults. J Clin Virol. 2015;69:125–132.
  • Srinivasan A, Wang C, Yang J, et al. Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1520–1527.
  • Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013;372:259–284.
  • Karron RA, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM, Griffin DE et al., editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 1497–1526.
  • Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–269.
  • Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines. 2011;10(10):1415–1433.
  • Rudraraju R, Jones BG, Sealy R, et al. Respiratory syncytial virus: current progress in vaccine development. Viruses. 2013;5(2):577–594.
  • Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis. 2014;209(11):1685–1692.
  • Anderson LJ, Dormitzer PR, Nokes DJ, et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013;31(Suppl 2):B209–B215.
  • Lambach P, Hombach J, Ortiz JR. A global perspective of maternal influenza immunization. Vaccine. 2015;33:6376–6379.
  • Wen SC, Williams JV. New approaches for immunization and therapy against human metapneumovirus. Clin Vaccine Immunol. 2015;22(8):858–866.
  • Graham BS, Anderson LJ. Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013;372:391–404.
  • Anderson LJ. Respiratory syncytial virus vaccine development. Semin Immunol. 2013;25(2):160–171.
  • Haynes LM. Progress and challenges in RSV prophylaxis and vaccine development. J Infect Dis. 2013;208(Suppl 3):S177–S183.
  • Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med. 2011;5(4):515–526.
  • Takimoto T, Hurwitz JL, Zhan X, et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol. 2005;18(2):255–266.
  • Chin J, Magoffin RL, Shearer LA, et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449–463.
  • Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89:435–448.
  • Beeler JA, Eichelberger MC. Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy. Microb Pathog. 2013;55:9–15.
  • Power UF, Nguyen TN, Rietveld E, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis. 2001;184(11):1456–1460.
  • Choi Y, Mason CS, Jones LP, et al. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 2012;25(3):193–203.
  • Piedra PA, Cron SG, Jewell A, et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine. 2003;21(19–20):2448–2460.
  • Brideau RJ, Walters RR, Stier MA, et al. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein. J Gen Virol. 1989;70:2637–2644.
  • Connors M, Collins PL, Firestone CY, et al. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol. 1991;65(3):1634–1637.
  • Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 1997;230(2):155–166.
  • Dagouassat N, Robillard V, Haeuw JF, et al. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine. 2001;19(30):4143–4152.
  • Schepens B, De Baets S, Sedyen K et al. Meeting presentation: SHe’s a novel target for RSV vaccination. 8th Respiratory Syncytial Virus Symposium; 2012 Sept 27–30; Santa Fe, NM.
  • Morrison TG, Walsh EE. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:285–306.
  • Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2015 Aug 10; pii:jiv406. [Epub ahead of print].

• This paper describes a clinical respiratory syncytial virus vaccine success in women of childbearing years.

  • Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7(11):e50852.
  • Swanson KA, Settembre EC, Shaw CA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011;108(23):9619–9624.
  • McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117.
  • McLellan JS, Chen M, Chang JS, et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol. 2010;84(23):12236–12244.
  • McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85(15):7788–7796.
  • Loomis RJ, Johnson PR. Gene-based vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:307–324.
  • Yang K, Varga SM. Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol. 2014;6:78–84.
  • Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011;162(1–2):80–99.
  • Le Bayon JC, Lina B, Rosa-Calatrava M, et al. Recent developments with live-attenuated recombinant paramyxovirus vaccines. Rev Med Virol. 2013;23(1):15–34.
  • Murawski MR, McGinnes LW, Finberg RW, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2010;84(2):1110–1123.
  • Karron RA, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine. 2012;30(26):3975–3981.
  • Fu YH, He JS, Wang XB, et al. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem Biophys Res Commun. 2010;395(1):87–92.
  • Mok H, Lee S, Utley TJ, et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol. 2007;81(24):13710–13722.
  • Crowe J, Mok H, Hedgecock J, et al. Alphavirus-based respiratory syncytial virus vaccine induces protection mediated by both humoral and cellular responses, even in the presence of passively-acquired antibodies. 7th International Respiratory Syncytial Virus Symposium; 2010 Dec 2–5; Rotterdam. p. 142.
  • Ishida N, Homma M. Sendai virus. Adv Virus Res. 1978;23:349–383.
  • Kuroya M, Ishida N. Newborn virus pneumonitis (type Sendai). II. The isolation of a new virus possessing hemagglutinin activity. Yokohama Med Bull. 1953;4(4):217–233.
  • Fukumi H, Nishikawa F, Kitayama T. A pneumotropic virus from mice causing hemagglutination. Jpn J Med Sci Biol. 1954;7(4):345–363.
  • Parker JC, Whiteman MD, Richter CB. Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents. Infect Immun. 1978;19(1):123–130.
  • Bousse T, Chambers RL, Scroggs RA, et al. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res. 2006;121(1):23–32.
  • Giorgi C, Blumberg BM, Kolakofsky D. Sendai virus contains overlapping genes expressed from a single mRNA. Cell. 1983;35(3 Pt 2):829–836.
  • Curran J, Kolakofsky D. Ribosomal initiation from an ACG codon in the Sendai virus P/C mRNA. EMBO J. 1988;7(1):245–251.
  • Vidal S, Curran J, Kolakofsky D. Editing of the Sendai virus P/C mRNA by G insertion occurs during mRNA synthesis via a virus-encoded activity. J Virol. 1990;64(1):239–246.
  • Hausmann S, Garcin D, Morel AS, et al. Two nucleotides immediately upstream of the essential A6G3 slippery sequence modulate the pattern of G insertions during Sendai virus mRNA editing. J Virol. 1999;73(1):343–351.
  • Lamb RA, Mahy BW, Choppin PW. The synthesis of Sendai virus polypeptides in infected cells. Virology. 1976;69(1):116–131.
  • Samal SK, Collins PL. RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. J Virol. 1996;70(8):5075–5082.
  • Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol. 1993;67(8):4822–4830.
  • Kolakofsky D, Pelet T, Garcin D, et al. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol. 1998;72(2):891–899.
  • Takimoto T, Bousse T, Coronel EC, et al. Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions. J Virol. 1998;72(12):9747–9754.
  • Lamb RA, Choppin PW. The synthesis of Sendai virus polypeptides in infected cells. II. Intracellular distribution of polypeptides. Virology. 1977;81(2):371–381.
  • Sanderson CM, McQueen NL, Nayak DP. Sendai virus assembly: M protein binds to viral glycoproteins in transit through the secretory pathway. J Virol. 1993;67(2):651–663.
  • Sanderson CM, Wu HH, Nayak DP. Sendai virus M protein binds independently to either the F or the HN glycoprotein in vivo. J Virol. 1994;68(1):69–76.
  • Heggeness MH, Smith PR, Choppin PW. In vitro assembly of the nonglycosylated membrane protein (M) of Sendai virus. Proc Natl Acad Sci U S A. 1982;79(20):6232–6236.
  • Ali A, Nayak DP. Assembly of Sendai virus: M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein. Virology. 2000;276(2):289–303.
  • Scheid A, Choppin PW. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus. Virology. 1974;57(2):475–490.
  • Scheid A, Choppin PW. The hemagglutinating and neuraminidase protein of a paramyxovirus: interaction with neuraminic acid in affinity chromatography. Virology. 1974;62(1):125–133.
  • Russell CJ, Luque LE. The structural basis of paramyxovirus invasion. Trends Microbiol. 2006;14(6):243–246.
  • Russell CJ, Jardetzky TS, Lamb RA. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J. 2001;20(15):4024–4034.
  • Lamb RA, Paterson RG, Jardetzky TS. Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology. 2006;344(1):30–37.
  • Huang RT, Rott R, Wahn K, et al. The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology. 1980;107(2):313–319.
  • Vidal S, Kolakofsky D. Modified model for the switch from Sendai virus transcription to replication. J Virol. 1989;63(5):1951–1958.
  • Kato A, Kiyotani K, Hasan MK, et al. Sendai virus gene start signals are not equivalent in reinitiation capacity: moderation at the fusion protein gene. J Virol. 1999;73(11):9237–9246.
  • Tokusumi T, Iida A, Hirata T, et al. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res. 2002;86(1–2):33–38.
  • Burke CW, Mason JN, Surman SL, et al. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 2011;7(7):e1002134.
  • Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J. 2008;27(10 Suppl):S126–S128.
  • Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003;171(10):4969–4973.
  • Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev. 2006;211:320–337.
  • Lyn D, Gill DS, Scroggs RA, et al. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J Gen Virol. 1991;72:983–987.
  • Dave VP, Allan JE, Slobod KS, et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology. 1994;199:376–383.
  • Smith FS, Portner A, Leggiadro RJ, et al. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology. 1994;205(2):453–461.
  • Sealy R, Jones BG, Surman SL, et al. Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1. Vaccine. 2010;28(41):6749–6756.

• This paper describes the long-term establishment of virus-specific IgA and IgG responses in respiratory tract tissues.

  • Rudraraju R, Surman S, Jones B, et al. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. Virology. 2011;410(2):429–436.

•• This paper demonstrates the robust and long-term immune responses induced by Sendai virus vaccinations.

  • Sangster M, Smith FS, Coleclough C, et al. Human parainfluenza virus-type 1 immunization of infant mice protects from subsequent Sendai virus infection. Virology. 1995;212:13–19.
  • Hurwitz JL, Soike KF, Sangster MY, et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine. 1997;15:533–540.
  • Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine. 2004;22(23–24):3182–3186.
  • Adderson E, Branum K, Sealy RE, et al. Safety and immunogenicity of an intranasal Sendai virus-based parainfluenza virus type 1 vaccine in 3–6 year old children. Clin Vaccine Immunol. 2015;22:298–303.

•• This manuscript demonstrates the safety and immunogenicity of Sendai virus in 3- to 6-year-old children.

  • Luongo C, Yang L, Winter CC, et al. Codon stabilization analysis of the “248” temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine. 2009;27(41):5667–5676.
  • Schickli JH, Kaur J, Tang RS. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures. Virus Res. 2012;169(1):38–47.
  • Henrickson KJ, Kingsbury DW, van Wyke Coelingh KL, et al. Neutralizing epitopes of human parainfluenza virus type 3 are conformational and cannot be imitated by synthetic peptides. Vaccine. 1991;9:243–249.
  • York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996;14:369–396.
  • Nagai Y, Kato A. Paramyxovirus reverse genetics is coming of age. Microbiol Immunol. 1999;43(7):613–624.
  • Sakai Y, Kiyotani K, Fukumura M, et al. Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Lett. 1999;456(2):221–226.
  • Kato A, Sakai Y, Shioda T, et al. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells. 1996;1(6):569–579.
  • Garcin D, Pelet T, Calain P, et al. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J. 1995;14(24):6087–6094.
  • Takimoto T, Hurwitz JL, Coleclough C, et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol. 2004;78(11):6043–6047.
  • Zhan X, Hurwitz JL, Krishnamurthy S, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine. 2007;25(52):8782–8793.
  • Zhan X, Slobod KS, Jones BG, et al. Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats. Int Immunol. 2015;27(5):229–236.
  • Prince GA, Jenson AB, Hemming VG, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol. 1986;57(3):721–728.
  • Jones BG, Sealy RE, Surman SL, et al. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine. 2014;32(26):3264–3273.

• This manuscript demonstrates that Sendai virus is protective in the presence of passively acquired antibodies, modeling the maternal antibodies of a 2-month-old infant.

  • Jones BG, Sealy RE, Rudraraju R, et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine. 2012;30(5):959–968.

•• This manuscript demonstrates the safety and efficacy of a Sendai virus –based respiratory syncytial virus vaccine in primates.

  • Ishii H, Matano T. Development of an AIDS vaccine using Sendai virus vectors. Vaccine. 2015;33:6061–6065.
  • Zhan X, Slobod KS, Krishnamurthy S, et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine. 2008;26(27–28):3480–3488.
  • Jones B, Zhan X, Mishin V, et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine. 2009;27(12):1848–1857.

•• This manuscript demonstrates that cocktails of Sendai virus can be used to protect against multiple paramyxoviruses at once.

  • Brown SA, Surman SL, Sealy R, et al. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses. 2010;2(2):435–467.
  • Yu S, Feng X, Shu T, et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine. 2008;26(48):6124–6131.
  • Skiadopoulos MH, Surman SR, Riggs JM, et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology. 2002;297(1):153–160.
  • Matano T, Kano M, Nakamura H, et al. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol. 2001;75(23):11891–11896.
  • Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med. 2004;199(12):1709–1718.
  • Graham BS, Crowe JE Jr. Immunization against viral diseases. In: Knipe DM, Howley PM, Griffin DE et al., editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 487–538.
  • Lievano F, Galea SA, Thornton M, et al. Measles, mumps, and rubella virus vaccine (M-M-RII): a review of 32 years of clinical and postmarketing experience. Vaccine. 2012;30(48):6918–6926.
  • Zachariah P, Stockwell MS. Measles vaccine- past, present and future. J Clin Pharmacol. 2015. DOI:10.1002/jcph.606.
  • Jaye A, Magnusen AF, Sadiq AD, et al. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J Clin Invest. 1998;102(11):1969–1977.
  • Chanock RM, Murphy BR, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia (PA): Lippincott Williams and Wilkins; 2001. p. 1341–1379.
  • Elliott MB, Pryharski KS, Yu Q, et al. Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. J Virol. 2004;78(11):5773–5783.
  • Javaherian K, Langlois AJ, Montefiori DC, et al. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J Virol. 1994;68(4):2624–2631.
  • Muramatsu M, Homma M. Trypsin action on the growth of Sendai virus in tissue culture cells. V. An activating enzyme for Sendai virus in the chorioallantoic fluid of the embryonated chicken egg. Microbiol Immunol. 1980;24(2):113–122.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.